References
- https://www.who.int/news-room/fact-sheets/detail/tuberculosis, [Accessed on 16/02/2022].
- A. MacNeil, P. Glaziou, C. Sismanidis, S. Maloney, and K. Floyd, Global epidemiology of tuberculosis and progress toward achieving global targets-2017, MMWR Morb. Mortal. Wkly. Rep. 68 (2019), pp. 263–266. doi:https://doi.org/10.15585/mmwr.mm6811a3.
- Y. Shinde, I. Ahmad, S. Surana, and H. Patel, The mur enzymes chink in the armour of Mycobacterium tuberculosis cell wall, Eur. J. Med. Chem. 222 (2021), pp. 113568. doi:https://doi.org/10.1016/j.ejmech.2021.113568.
- E.B. Chahine, L.R. Karaoui, and H. Mansour, Bedaquiline: A novel diarylquinoline for multidrug-resistant tuberculosis, Ann. Pharmacother. 48 (2014), pp. 107–115. doi:https://doi.org/10.1177/1060028013504087.
- M.V. Worley and S.J. Estrada, Bedaquiline: A novel antitubercular agent for the treatment of multidrug-resistant tuberculosis, Pharmacotherapy 34 (2014), pp. 1187–1197. doi:https://doi.org/10.1002/phar.1482.
- M.J. Lobo, R. Ray, and G.G. Shenoy, Gaining deeper insights into the surface binding of bedaquiline analogues with the ATP synthase subunit C of Mycobacterium tuberculosis using molecular docking, molecular dynamics simulation and 3D-QSAR techniques, New J. Chem. 44 (2020), pp. 18831–18852. doi:https://doi.org/10.1039/D0NJ02062A.
- E. Cox and K. Laessig, FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis, N. Engl. J. Med. 371 (2014), pp. 689–691. doi:https://doi.org/10.1056/NEJMp1314385.
- J. Guillemont, C. Meyer, A. Poncelet, X. Bourdrez, and K. Andries, Diarylquinolines, synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207, Future Med. Chem. 3 (2011), pp. 1345–1360. doi:https://doi.org/10.4155/fmc.11.79.
- Treatment of patients with MDR-TB Briefing document, TMC 207 (bedaquiline). Anti-infective Drugs Advisory Committee, NDA 204-384. (28 November 2014)
- I. Ahmad, H. Jadhav, Y. Shinde, V. Jagtap, R. Girase, and H. Patel, Optimizing bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors, Silico Pharmacol. 23 (2021), pp. 23. doi:https://doi.org/10.1007/s40203-021-00086-x.
- M.C. Sanguinetti and M. Tristani-Firouzi, hERG potassium channels and cardiac arrhythmia, Nature 440 (2006), pp. 463–469. doi:https://doi.org/10.1038/nature04710.
- E. Pontali, G. Sotgiu, S. Tiberi, L. D’Ambrosio, R. Centis, and G.B. Migliori, Cardiac safety of bedaquiline: A systematic and critical analysis of the evidence, Eur. Respir. J. 16 (2017), pp. 1701462. doi:https://doi.org/10.1183/13993003.01462-2017.
- G.J. Fox and D. Menzies, A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis, Infect. Dis. Ther. 2 (2013), pp. 123–144. doi:https://doi.org/10.1007/s40121-013-0009-3.
- https://www.ncbi.nlm.nih.gov/books/NBK548859/, [Accessed on 16/02/2022].
- E.Y. Salifu, C. Agoni, F.A. Olotu, and M.E. Soliman, Triple mycobacterial ATP-synthase mutations impedes bedaquiline binding: Atomistic and structural perspectives, Comput. Biol. Chem. 85 (2020), pp. 107204. doi:https://doi.org/10.1016/j.compbiolchem.2020.107204.
- M. Noorsuzana, Chapter 14 - Recent advancement and future perspective for the treatment of multidrug-resistant tuberculosis, in Nanotechnology Based Approaches for Tuberculosis Treatment, P. Kesharwani, ed., Acedmic press, London, 2020, pp. 231–250.
- E.M. Svensson, S. Murray, M.O. Karlsson, and K.E. Dooley, Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug, J. Antimicrob. Chemother. 70 (2015), pp. 1106–1114. doi:https://doi.org/10.1093/jac/dku504.
- H. Yang, L. Sun, Z. Wang, W. Li, G. Liu, and Y. Tang, ADMETopt: A web server for ADMET optimization in drug design via scaffold hopping, J. Chem. Inf. Model. 58 (2018), pp. 2051–2056. doi:https://doi.org/10.1021/acs.jcim.8b00532.
- H. Yang, C. Lou, L. Sun, J. Li, Y. Cai, Z. Wang, W. Li, G. Liu, and Y. Tang, AdmetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties, Bioinformatics 15 (2019), pp. 1067–1069.
- https://www.rcsb.org/structure/4V1F, [Accessed on 16/02/2022].
- Schrödinger, Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY.
- G.M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman, Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des. 27 (2013), pp. 134–221. doi:https://doi.org/10.1007/s10822-013-9644-8.
- T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, and J.L. Banks, Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, J. Med. Chem. 47 (2004), pp. 1750–1759. doi:https://doi.org/10.1021/jm030644s.
- I. Ahmad, M. Shaikh, S. Surana, A. Ghosh, and H. Patel, p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): Emergence of fourth-generation EGFR inhibitor, J. Biomol. Struct. Dyn. 11 (2020), pp. 1–14.
- J. Li, R. Abel, K. Zhu, Y. Cao, S. Zhao, and R.A. Friesner, The VSGB 2.0 model: A next generation energy model for high resolution protein structure modelling, Proteins 79 (2011), pp. 2794–2812. doi:https://doi.org/10.1002/prot.23106.
- H. Patel, R. Pawara, and S. Surana, In-silico evidence for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition, Comput. Biol. Chem. 74 (2018), pp. 167–189. doi:https://doi.org/10.1016/j.compbiolchem.2018.03.026.
- H.M. Patel, I. Ahmad, R. Pawara, M. Shaikh, and S. Surana, In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): A combined approach of structure-based virtual screening and molecular dynamics simulation, J. Biomol. Struct. Dyn. 39 (2021), pp. 1491–1505. doi:https://doi.org/10.1080/07391102.2020.1734092.
- Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2021-1. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2021–1.
- H. Behzadi, P. Roonasi, D. van der Spoel, and S. Manzetti, Relationship between electronic properties and drug activity of seven quinoxaline compounds: A DFT study, J. Mol. Struct. 1091 (2015), pp. 196–202. doi:https://doi.org/10.1016/j.molstruc.2015.03.001.
- A.D. Bochevarov, E. Harder, T.F. Hughes, J.R. Greenwood, D.A. Braden, D.M. Philipp, D. Rinaldo, M.D. Hall, J. Zhang, and R.A. Friesner, Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences, Int. J. Quant. Chem. 113 (2013), pp. 2110–2142. doi:https://doi.org/10.1002/qua.24481.
- U. Panwar and S.K. Singh, Atom-based3D-QSAR, molecular docking, DFT, and simulation studies of acylhydrazone, hydrazine, and diazene derivatives as IN-LEDGF/p75 inhibitors, Struct. Chem. 32 (2021), pp. 337–352. doi:https://doi.org/10.1007/s11224-020-01628-3.
- P. Rydberg, D.E. Gloriam, J. Zaretzki, C. Breneman, and L. Olsen, SMARTCyp: A 2D method for prediction of cytochrome P450-mediated drug metabolism, ACS Med. Chem. Lett. 3 (2010), pp. 96–100. doi:https://doi.org/10.1021/ml100016x.
- P. Rydberg, M. Rostkowski, D.E. Gloriam, and L. Olsen, The contribution of atom accessibility to site of metabolism models for cytochromes P450, Mol. Pharm. 10 (2013), pp. 1216–1223. doi:https://doi.org/10.1021/mp3005116.
- H. Patel, H. Jadhav, I. Ansari, R. Pawara, and S. Surana, Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors, Eur. J. Med. Chem. 1 (2019), pp. 1–9. doi:https://doi.org/10.1016/j.ejmech.2019.01.073.
- S. Kundu, G. Biukovic, G. Grüber, and T. Dick, Bedaquiline targets the ε subunit of mycobacterial F-ATP synthase, Antimicrob. Agents Chemother. 21 (2016), pp. 6977–6979. doi:https://doi.org/10.1128/AAC.01291-16.
- H. Patel, R. Pawara, K. Pawara, F. Ahmed, A. Shirkhedkar, and S. Surana, A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity, Tuberculosis 117 (2019), pp. 79–84. doi:https://doi.org/10.1016/j.tube.2019.06.005.
- R. Pawara, I. Ahmad, D. Nayak, S. Wagh, A. Wadkar, A. Ansari, S. Belamkar, S. Surana, C.N. Kundu, C. Patil, and H. Patel, Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M non-small-cell lung cancer (NSCLC), Bioorg. Chem. 115 (2021), pp. 105234. doi:https://doi.org/10.1016/j.bioorg.2021.105234.
- H.S. Sutherland, A. Tong, P.J. Choi, D. Conole, A. Blaser, S.G. Franzblau, C.B. Cooper, A.M. Upton, M.U. Lotlikar, W.A. Denny, and B.D. Palmer, Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles, Bioorg. Med. Chem. 26 (2018), pp. 1797–1809. doi:https://doi.org/10.1016/j.bmc.2018.02.026.
- T. Koopmans, Über die Zuordnung von Wellenfunktionen und Eigenwerten zu den einzelnen Elektronen eines Atoms, Physica 1 (1934), pp. 104–113. doi:https://doi.org/10.1016/S0031-8914(34)90011-2.
- I.M. Othman, M.H. Mahross, M.A. Gad-Elkareem, M. Rudrapal, N. Gogoi, D. Chetia, K. Aouadi, M. Snoussi, and A. Kadri, Toward a treatment of antibacterial and antifungal infections: Design, synthesis and in vitro activity of novel arylhydrazo-thiazolylsulfonamides analogues and their insight of DFT, docking and molecular dynamic simulations, J. Mol. Struct. 5 (2021), pp. 130862. doi:https://doi.org/10.1016/j.molstruc.2021.130862.
- M.S. GanesanK, K. Raja, S. Murugesa, B.K. Kumar, G. Rajagopal, and S. Thirunavukkarasu, Synthesis, biological evaluation, molecular docking, molecular dynamics and DFT studies of quinoline-fluoroproline amide hybrids, J. Mol. Struct. 1217 (2020), pp. 128360. doi:https://doi.org/10.1016/j.molstruc.2020.128360.
- S. Bhowmick, N.A. AlFaris, J.Z. ALTamimi, Z.A. ALOthman, T.S. Aldayel, S.M. Wabaidur, and M.A. Islam, Screening and analysis of bioactive food compounds for modulating the CDK2 protein for cell cycle arrest: Multi-cheminformatics approaches for anticancer therapeutics, J. Mol. Struct. 1216 (2020), pp. 128316. doi:https://doi.org/10.1016/j.molstruc.2020.128316.
- M.A. Jordaan, O. Ebenezer, N. Damoyi, and M. Shapi, Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz, Heliyon 6 (2020), pp. e04642. doi:https://doi.org/10.1016/j.heliyon.2020.e04642.
- M. Amala, S. Rajamanikandan, D. Prabhu, K. Surekha, and J. Jeyakanthan, Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: Combined molecular docking and molecular dynamics approaches, J. Biomol. Struct. Dyn. 37 (2019), pp. 394–410. doi:https://doi.org/10.1080/07391102.2018.1427633.
- J.S. Murray and P. Politzer, The electrostatic potential: An overview, Wiley Interdiscip. Rev. Comput. Mol. Sci. 1 (2011), pp. 153–163. doi:https://doi.org/10.1002/wcms.19.